KeyBank National Association’s GoodRx Holdings GDRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-28,813
Closed -$134K 1073
2022
Q4
$134K Sell
28,813
-25,959
-47% -$128K ﹤0.01% 1026
2022
Q3
$256K Sell
54,772
-17,387
-24% -$110K ﹤0.01% 903
2022
Q2
$427K Sell
72,159
-71,082
-50% -$791K ﹤0.01% 732
2022
Q1
$2.77M Sell
143,241
-272,331
-66% -$6.25M 0.01% 337
2021
Q4
$13.6M Sell
415,572
-293,645
-41% -$11.8M 0.05% 196
2021
Q3
$29.1M Buy
709,217
+14,510
+2% +$526K 0.13% 138
2021
Q2
$25M Buy
694,707
+2,478
+0.4% +$91.4K 0.11% 148
2021
Q1
$27M Buy
692,229
+492,862
+247% +$22.2M 0.13% 141
2020
Q4
$8.04M Buy
+199,367
New +$9.16M 0.04% 218

Other funds holding GDRX

KeyBank National Association's GDRX Position: Q1 2023 in Review

KeyBank National Association sold out of GoodRx Holdings (GDRX) in Q1 2023, closing a stake of 28,813 shares — an estimated $134K sold.

KeyBank National Association first reported a position in GDRX in Q4 2020 and held it in 9 quarters. The position peaked at $29.1M in Q3 2021. 159 funds tracked by Wall St. Rank hold GDRX as of Q1 2023.

  • KeyBank National Association reported no remaining GoodRx Holdings position as of Q1 2023 after selling out during the quarter.
  • KeyBank National Association sold 28,813 GoodRx Holdings shares in Q1 2023, an estimated $134K.
  • KeyBank National Association first reported a position in GoodRx Holdings in Q4 2020 and held it in 9 quarters.
  • KeyBank National Association's GoodRx Holdings position peaked at $29.1M in Q3 2021.
  • 159 funds tracked by Wall St. Rank held GoodRx Holdings as of Q1 2023.

Based on KeyBank National Association's 13F filing for Q1 2023, filed 10 May 2023.